GlassScriptPhysician profile
Bruce G Watrous
NPI 1609859958
$6,261.22
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,820 · 2020: $1,563 · 2021: $269 · 2022: $233 · 2023: $257 · 2024: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $377.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,330.81 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $939.72 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $418.01 | 2019-2020 | |
| Amgen INC. | $375.81 | 2019-2024 | Repatha |
| Pfizer INC. | $277.52 | 2019-2024 | |
| Allergan, INC. | $258.65 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $241.35 | 2022-2023 | Nuzyra |
| Bayer Healthcare Pharmaceuticals INC. | $228.00 | 2022-2023 | |
| Novo Nordisk INC | $205.34 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $161.06 | 2019-2024 | |
| Abbott Laboratories | $144.67 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $131.47 | 2019 | |
| Esperion Therapeutics, INC. | $126.32 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.84 | 2019-2020 | |
| Glaxosmithkline, LLC. | $49.62 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $46.66 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $45.10 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $44.20 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $28.55 | 2024 | Camzyos |
| Edwards Lifesciences Corporation | $25.10 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.41 | 2019 | |
| Heartflow, INC. | $20.23 | 2023 | Ffrct |
| Lilly USA, LLC | $13.90 | 2020 | |
| Sanofi-Aventis U.S. LLC | $13.90 | 2019 | |
| Altathera Pharmaceuticals LLC | $10.98 | 2024 | Sotalol Hydrochloride |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Watrous listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.